Additionally, the LDL-lowering effect of ezetimibe was significantly greater in DM [17], suggesting the potentially beneficial role of ezetimibe as a NPC1L1 inhibitor in the treatment of DM with dyslipidemia and vascular dysfunction [8,9]. Here, NPC1L1 is linked to metabolic syndrome.